Immunogenicity of BRCA1-deficient ovarian cancers is driven through DNA sensing and is augmented by PARP inhibition

被引：0

作者：

Bruand, M. ^{[1
]}

Barras, D. ^{[1
,2
]}

Mina, M. ^{[3
]}

Lanitis, E. ^{[1
]}

Chong, C. ^{[1
]}

Dorier, J. ^{[2
]}

Walton, J. ^{[4
]}

Bassani-Sternberg, M. ^{[1
]}

Kandalaft, L. ^{[1
]}

McNeish, I. A. ^{[5
]}

Swisher, E. ^{[6
]}

Delorenzi, M. ^{[1
]}

Ren, B. ^{[7
,8
]}

Ciriello, G. ^{[3
]}

Irving, M. ^{[1
]}

Rusakiewicz, S. ^{[1
]}

Foukas, P. ^{[1
]}

Martinon, F. ^{[9
]}

Dangaj, D. ^{[1
]}

Coukos, G. ^{[1
]}

机构：

[1] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, Epalinges, Switzerland

[2] Univ Lausanne, Vital IT, Swiss Inst Bioinformat SIB, Epalinges, Switzerland

[3] Univ Lausanne, Dept Computat Biol, Lausanne, Switzerland

[4] Imperial Coll London, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Hammersmith Hosp, London, England

[5] Imperial Coll London, Dept Surg & Canc, London, England

[6] Univ Washington, Seattle Canc Care Alliance, Med, Seattle, WA 98195 USA

[7] Ludwig Inst Canc Res, San Diego Sch Med, Dept Cellular & Mol Med, Inst Genom Med, La Jolla, CA USA

[8] Univ Calif San Diego, La Jolla, CA 92093 USA

[9] Univ Lausanne, Dept Biochem, Lausanne, Switzerland

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1876PD

引用

页数：1

共 50 条

[41] Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability
Whalen, Jenna M.
Earley, Jillian
Wisniewski, Christi
Mercurio, Arthur M.
Cantor, Sharon B.
NATURE CANCER, 2025, 6 (02) : 278 - 291
[42] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
Zhang, Di
Singh, Bijay
Moerland, Jessica
Mitchell, Owen
Lockwood, Lizbeth
Carapellucci, Sarah
Sridhar, Srinivas
Liby, Karen T.
SCIENTIFIC REPORTS, 2021, 11 (01)
[43] Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Bruand, Marine
Barras, David
Mina, Marco
Ghisoni, Eleonora
Morotti, Matteo
Lanitis, Evripidis
Fahr, Noemie
Desbuisson, Mathieu
Grimm, Alizee
Zhang, Hualing
Chong, Chloe
Dagher, Julien
Chee, Sora
Tsianou, Theodora
Dorier, Julien
Stevenson, Brian J.
Iseli, Christian
Ronet, Catherine
Bobisse, Sara
Genolet, Raphael
Walton, Josephine
Bassani-Sternberg, Michal
Kandalaft, Lana E.
Ren, Bing
McNeish, Iain
Swisher, Elizabeth
Harari, Alexandre
Delorenzi, Mauro
Ciriello, Giovanni
Irving, Melita
Rusakiewicz, Sylvie
Foukas, Periklis G.
Martinon, Fabio
Laniti, Denarda Dangaj
Coukos, George
CELL REPORTS, 2021, 36 (03):
[44] Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor
Liu, Jianlin
Adhav, Ragini
Miao, Kai
Su, Sek Man
Mo, Lihua
Chan, Un In
Zhang, Xin
Xu, Jun
Li, Jianjie
Shu, Xiaodong
Zeng, Jianming
Zhang, Xu
Lyu, Xueying
Pardeshi, Lakhansing
Tan, Kaeling
Sun, Heng
Wong, Koon Ho
Deng, Chuxia
Xu, Xiaoling
NATURE COMMUNICATIONS, 2020, 11 (01)
[45] Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Ratz, Leonie
Brambillasca, Chiara
Bartke, Leandra
Huetzen, Maxim A.
Goergens, Jonas
Leidecker, Orsolya
Jachimowicz, Ron D.
van de Ven, Marieke
Proost, Natalie
Siteur, Bjorn
de Korte-Grimmerink, Renske
Bouwman, Peter
Pulver, Emilia M.
de Bruijn, Roebi
Isensee, Joerg
Hucho, Tim
Pandey, Gaurav
van Lohuizen, Maarten
Mallmann, Peter
Reinhardt, Hans Christian
Jonkers, Jos
Puppe, Julian
BREAST CANCER RESEARCH, 2022, 24 (01)
[46] Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Leonie Ratz
Chiara Brambillasca
Leandra Bartke
Maxim A. Huetzen
Jonas Goergens
Orsolya Leidecker
Ron D. Jachimowicz
Marieke van de Ven
Natalie Proost
Bjørn Siteur
Renske de Korte-Grimmerink
Peter Bouwman
Emilia M. Pulver
Roebi de Bruijn
Jörg Isensee
Tim Hucho
Gaurav Pandey
Maarten van Lohuizen
Peter Mallmann
Hans Christian Reinhardt
Jos Jonkers
Julian Puppe
Breast Cancer Research, 24
[47] The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance
Da Costa, Alexandre Andre B. A.
Bose, Arindam
Martignetti, David
Ayala-Zambrano, Cecilia
Ravindranathan, Ramya
Sadatrezaei, Golbahar
Jiao, Yuqing
Kochupurakkal, Bose
Nguyen, Huy
Lazaro, Jean-Bernard
Parmar, Kalindi
Shapiro, Geoffrey I.
D'Andrea, Alan D.
CANCER RESEARCH, 2023, 83 (07)
[48] Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor
Jianlin Liu
Ragini Adhav
Kai Miao
Sek Man Su
Lihua Mo
Un In Chan
Xin Zhang
Jun Xu
Jianjie Li
Xiaodong Shu
Jianming Zeng
Xu Zhang
Xueying Lyu
Lakhansing Pardeshi
Kaeling Tan
Heng Sun
Koon Ho Wong
Chuxia Deng
Xiaoling Xu
Nature Communications, 11
[49] Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells
Goldberg, Michael S.
Xing, Deyin
Ren, Yin
Orsulic, Sandra
Bhatia, Sangeeta N.
Sharp, Phillip A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (02) : 745 - 750
[50] Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast
Puppe, J.
Brambillasca, C.
Ratz, L.
Bartke, L.
van de Ven, M.
Bouwman, P.
van Tellingen, O.
Isensee, J.
Hucho, T.
van Lohuizen, M.
Malter, W.
Schmutzler, R.
Mallmann, P.
Jonkers, J.
Reinhardt, C.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E104 - E104

← 1 2 3 4 5 →